

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Technology Appraisal no. 55; Paclitaxel for the first line treatment of ovarian cancer

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Actavis UK (paclitaxel) • Bristol-Myers Squibb (paclitaxel) • Hospira UK (paclitaxel) • Pliva Pharma (paclitaxel) • Teva UK (paclitaxel) • Wockhardt UK (paclitaxel) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Age Concern and Help the Aged • Association for Children with Life Threatening or Terminal Conditions (ACT) • Black Health Agency • CANCERactive • Cancer Black Care • Cancer Equality • Cancer Voices • Chinese National Healthy Living Centre • CLIC Sargent • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Gynae C • Helen Rollason Heal Cancer Charity • Help Adolescents with Cancer • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Actavis UK (gemcitabine) • Bristol-Myers Squibb (carboplatin, cisplatin) • Eli Lilly and Company (gemcitabine) • GlaxoSmithKline (topotecan) • Hameln Pharmaceuticals (doxorubicin) • Hospira UK (carboplatin, cisplatin, doxorubicin) • Pfizer (cisplatin, doxorubicin) • Pliva Pharma (carboplatin) • Roche Products (bevacizumab) • Schering-Plough (doxorubicin) • Sun Pharmaceuticals (gemcitabine) • Teva UK (carboplatin, cisplatin,

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • National Council for Palliative Care • Ovacome • Ovarian Cancer Action • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Teenage Cancer Trust • Tenovus Cancer Information Centre • Well Being of Women • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the Elderly • British Geriatrics Society • British Gynaecological Cancer Society • British Oncological Association (BOA) • British Psychosocial Oncology Society • Cancer Networks Pharmacists Forum • Cancer Research UK • Children's Cancer and Leukaemia Group • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians & Gynaecologists • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Islington 	<p>doxorubicin, gemcitabine)</p> <ul style="list-style-type: none"> • Wockhardt UK (carboplatin, cisplatin, doxorubicin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Eve appeal • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer • National Collaborating Centre for Women's and Children's Health <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • none

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS West Kent • Welsh Assembly Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute)